Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

BTYNB IMP1 Inhibitor

  • Zoom
    BTYNB IMP1 Inhibitor
  • BTYNB IMP1 Inhibitor
Cat No: 25623
Biochemicals - More Biochemicals
Cayman

BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhi...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 2-[[(5-bromo-2-thienyl)methylene]amino]-benzamide
Correlated keywords:
  • IMP-1 cMyc m-RNA ?TrCP1 ?-TrCP-1 ?TrCP-1 SKMEL-2 IGROV1 SKMEL2 SK- MEL2 ES2 T47DKBluc T-47D T-47-D
Product Overview:
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).{43310} It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Size 1 mg
Shipping dry ice
CAS Number 304456-62-0
Molecular Formula C12H9BrN2OS
SMILES O=C(N)C1=CC=CC=C1/N=C/C2=CC=C(Br)S2
Molecular Weight 309,2
Formulation A solid
Purity ≥95%
Custom Code 2930.90
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search